Myeloid proliferations associated with Down syndrome

被引：0
作者：
Alan B. Cantor
机构：
[1] Harvard Medical School,Division of Pediatric Hematology–Oncology, Boston Children’s Hospital/Dana
[2] Harvard Stem Cell Institute,Farber Cancer Institute
来源：
Journal of Hematopathology | 2015年 / 8卷
关键词：
Down syndrome; Myeloid proliferation; Myeloproliferative disorder;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
A subset of Down syndrome (DS) (trisomy 21) neonates is born with a unique erythromegakaryocytic myeloproliferative disorder that spontaneously resolves over the first few months of life (DS-transient abnormal myelopoiesis (DS-TAM); previously called DS-transient myeloproliferative disorder (DS-TMD) and DS-transient leukemia (DS-TL)). These infants are at high risk for developing subsequent acute megakaryoblastic leukemia (myeloid leukemia associated with Down syndrome (ML-DS); previously called DS-acute megakaryoblastic leukemia (DS-AMKL)). The molecular basis for DS-TAM/ML-DS remained mysterious for a long period of time. However, new genetic insights have been gained over the past 12 years that have begun to decipher the pathophysiology of this unusual disorder.
引用
收藏
页码：169 / 176
页数：7
相关论文
共 494 条
[1]  
Roberts I(2013)GATA1-mutant clones are frequent and often unsuspected in babies with Down syndrome: identification of a population at risk of leukemia Blood 122 3908-3917
[2]  
Alford K(2009)The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes Blood 114 937-951
[3]  
Hall G(2003)Transient leukaemia—a benign form of leukaemia in newborn infants with trisomy 21 Br J Haematol 120 930-938
[4]  
Juban G(2000)The management of neoplastic disorders of haematopoiesis in children with Down’s syndrome Br J Haematol 110 512-524
[5]  
Richmond H(2007)Incidence and clinical implications of GATA1 mutations in newborns with Down syndrome Blood 110 2128-2131
[6]  
Norton A(2006)A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children’s Oncology Group (COG) study POG-9481 Blood 107 4606-4613
[7]  
Vallance G(2008)Treatment and prognostic impact of transient leukemia in neonates with Down syndrome Blood 111 2991-2998
[8]  
Perkins K(2008)Risk factors for early death in neonates with Down syndrome and transient leukaemia Br J Haematol 142 610-615
[9]  
Marchi E(2011)Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children’s Oncology Group Study A2971 Blood 118 6752-6759
[10]  
McGowan S(1992)Leukemia in Down syndrome: a review Pediatr Hematol Oncol 9 139-149
12345678910